Abstract
We compared the clinical value of minimal residual disease (MRD) monitoring by cytofluorimetric methods, Wilms tumor gene 1 (WT1) expression and the study of nucleophosmin gene (NPM) mutations in a series of 26 patients with NPM-mutated de novo acute myeloid leukemia (NPM-AML) who achieved complete hematological remission after conventional chemotherapy. The relapse risk was significantly lower only in patients achieving a NPM molecular complete response (NPM mol-CR) and confirmed NPM mol-CR (non-detectable NPM mutations in two consecutive marrow samples). The disease-free survival (DFS) of patients achieving a
Original language | English |
---|---|
Pages (from-to) | 2214-2217 |
Number of pages | 4 |
Journal | Leukemia and Lymphoma |
Volume | 53 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2012 |
Keywords
- AML
- MRD
- NPM
- WT1
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research